|
Previous SEBIO companies selected to present have raised more than
$2 billion in venture capital funding.
Companies who have previously presented at SEBIO include:
| Altea Therapeutics |
Biolex, Inc. |
| Applied Genetic Technologies Corporation |
Regado Biosciences |
| Argos Therapeutics |
Targacept, Inc. |
Apply to Present at the SEBIO Investor Forum
Companies applying to present at the SEBIO Forum are classified as either EARLY/Stage companies or MAIN/Stage companies. The Selection
Criteria used to judge the candidates will be applied equally to
both groups, recognizing the likely distinctions in factors such as
the completeness of the management team, funding history, and stage
of technology development.
Apply
to Present at the SEBIO Investor Forum today!
EARLY/Stage Company Profile
- No prior institutional funding (Seed or ‘A’ Round),
regardless of the stage of development of the underlying technology
and/or completeness of the management team.
- Management team may be less developed and, in some cases, be limited
to an academic investigator, who is the principal founder.
- May or may not have license agreement(s) in place; however, these
should be contemplated as part of the continuing development of the
company.
- The selection committee will take special notice
of those applicants who either have managers in place that are legitimately recognized
as serial entrepreneurs or have progressed the company’s technology
through funding vehicles other than venture capital. These applicants
may, at the discretion of the selection committee, be chosen to present
on the MAIN/Stage with the mid- to late-stage companies before the full conference audience.
Presentation Format
New this year, each company has the option of participating in a 30 minute, web-based virtual presentation and consultation session with a small panel of advisors 2-4 weeks before the SEBIO Investor Forum. On site at the Investor Forum, each company will meet with a specifically matched advisory panel during an interactive, hour-long session. Advisory panels are comprised of 6-10 individuals from active life sciences venture funds, experienced life sciences managers, serial entrepreneurs, and service providers. The company representatives will present their opportunity, including their "elevator pitch," 10-12 minute PowerPoint presentation, and business plan. The advisory panel members will provide specifically relevant feedback designed to assist the company in maximizing efforts in the future. These sessions are closed to other conference attendees in an effort to enhance the discourse between the panel members and the company representatives and create an intimate networking environment.
Each advisory panel will select one representative from its group that they believe to be the strongest and best prepared EARLY/Stage company. These selected companies will then present their opportunities in a traditional venture conference venue to the full conference audience. The selected companies will be judged by an elite group of senior venture capitalists on the quality of the opportunity and the effectiveness of the presentation. The overall "winner" will be announced in a special ceremony the following day and recognized publicly for their success at this year's conference.
Back to Top
MAIN/Stage Company Profile
- Completed one or more investment rounds attributable to qualified
venture capital firms
- Active, credible management team
- Advanced in the development cycle for their technology or product
opportunity
Presentation Format
New this year, the MAIN/Stage company session will consist of alternating company presentations with panel discussions featuring company success stories. Selected companies will be allotted approximately 10 minutes to present and a single-track format will be followed so that all conference attendees have the opportunity to view all presentations.
Companies chosen to present may be required to participate in an on-site practice session, primarily to ensure successful transfer of the presentation materials and familiarize the presenter with the format and venue.
Back to Top
Selection
Criteria
Sector
All candidates for both programs must come from the life sciences
sector. Broadly defined, this includes products or services relating
to biotechnology (i.e., genomics, proteomics, drug discovery, etc.),
pharmaceuticals, biomedical engineering, agricultural biotechnology,
medical devices, bioinformatics, functional and pharmacogenomics, as
well as other related technologies. SEBIO will also accept applications
from healthcare information systems companies that support the above
activities.
Stage
All candidates must be privately held companies. The stage of development
may range from early to late. For purposes of categorizing the candidates,
those that have no previous institutional funding (seed or ‘A’
Round), regardless of the stage of development of the underlying technology
and/or completeness of the management team, will be designated as EARLY/Stage
companies. Those companies with one or more investment rounds attributable
to qualified venture capital firms will be designated as MAIN/Stage
companies.
Growth Potential
The company must exhibit a business model suitable to provide an appropriate
return for the venture capital investor.
Exit Strategy
The company must contemplate a suitable exit strategy for the venture
investor, for example, through sale or merger of the company or by initial
public offering (IPO).
Management Team
The company should have credible management with obvious sector expertise that is consistent with its current stage of development. The management team need not be complete; however, critical managers for that particular enterprise at its current stage of development should be in place. It is expected that management teams for candidate companies that are designated as EARLY/Stage will be less well developed and, in some cases, limited to an academic investigator who is the principal founder.
Sustainable Competitive Advantage
The company should have a distinct advantage over competitors, including
both direct competitors and substitute technologies. Additionally, the
company must exhibit an appreciation of the value of proprietary technologies,
as evidenced, for example, by a maturing intellectual property portfolio
and appropriate licenses securing access to other critical technologies.
It is recognized that EARLY/Stage candidates may not have license agreements in place to secure
exclusive use of their underlying technologies; however, these should
be contemplated as part of the continuing development of the company.
Market Acceptance and Potential
The company must show the market potential for the company's product
or service, as well as the capturable market. In general, the market
potential should exceed (1) $50 million for a diagnostic,
(2) $100 million for a medical device, and (3) $250 million for a therapeutic
compound.
Financing History
For MAIN/Stage companies, preference will be shown
to companies with a history of financing involving some measure of due
diligence.
SEBIO History
Companies that previously participated at earlier SEBIO Investor Forums, either presenting on the MAIN/Stage or participating in the EARLY/Stage program, are eligible for consideration. Preference will be shown to companies that have reached important milestones since their last presentation.
Back to Top
Apply to
Present today!
|
